TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04983264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT021601
Description: Tablets and capsules which contain GBT021601 drug substance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT021601
Description: Tablets and capsules which contain GBT021601 drug substance
Study: NCT05736068

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment
Description: If allocated to non-surgical group, cast optimization in the outpatient clinic may be necessary if the cast from the emergency room is considered insufficient.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment
Description: Closed reduction with or without fixation
Study: NCT06281028

Intervention type: DEVICE
Group type: OTHER
Intervention: SOLACEA-H/HYDROLINK-NVU
Description: Patients will receive 6 sessions of washout treatment, followed by a gradual tapering phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the SOLACEA-H, followed by 6 washout sessions, then again a gradual reduction phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the HYDROLINK-NVU.

Intervention type: DEVICE
Group type: OTHER
Intervention: HYDROLINK-NVU/SOLACEA-H
Description: Patients will receive 6 sessions of washout treatment, followed by a gradual tapering phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the HYDROLINK-NVU, followed by 6 washout sessions, then again a gradual reduction phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the SOLACEA-H.
Study: NCT05844514

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Patients must be fasted for a minimum of four hours prior to breath sample collection. For patients undergoing colonoscopy or surgery, breath samples must be obtained prior to patients receiving bowel preparation in either outpatient clinic or pre-assessment clinic.

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Patients must be fasted for a minimum of four hours prior to breath sample collection. For patients undergoing colonoscopy or surgery, breath samples must be obtained prior to patients receiving bowel preparation in either outpatient clinic or pre-assessment clinic.
Study: NCT04719390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Maternal-Focused Message: When randomized to receive a maternal-focused message, participants will receive a message that is focused on the transition to motherhood and the joys and challenges of caring for a newborn.~Drinking-Focused Message:~When randomized to receive a drinking-focused message, participants will receive a message that is focused on reducing alcohol use.~All messages of both types are designed to map onto behavior change techniques that are empirically supported for alcohol use.
Study: NCT05426629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Glow
Description: The Venus Glow hydradermabrasion device is a class 1 device trimodality dermal system consisting of vacuum, 360 degrees rotating tip and two jet streams of saline.~Adjustable vacuum deep cleanses the pores by pulling up daily dirt and debris, dry and dead skin cells, and excess sebum from the stratum corneum. It helps increase the microcirculation.~The 360-degree rotation helps in spreading the saline evenly, which is expelled from two ultra-fine jet streams. This micro massaging helps in faster release of nutrients from the skin. The jet stream is smaller than the average pore size measuring 50- 70 microns each, enabling the jet stream to deep clean each pore.
Study: NCT06358651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasedienol Nasal Spray
Description: Nasal spray delivered 20 minutes before the PSC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: Nasal spray delivered 20 minutes before the PSC
Study: NCT05512377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brigimadlin
Description: brigimadlin
Study: NCT06447688

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Verapamil
Description: Prevent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: Prevent
Study: NCT05560529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT
Description: Applying DBT modules in group format over 20 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Giving TAU (usual pharmacotherapy in BED) over 20 weeks

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Plasma Ghrelin
Description: Measuring fasting plasma ghrelin pre and post treatment in both arms

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Ghrelin
Description: Measuring fasting plasma ghrelin pre and post treatment in both arms
Study: NCT06522308

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatobiliary ultrasound
Description: The presence of cholelithiasis in patients with umbilical hernia is detected by hepatobiliary ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: Umbilical region superficial tissue ultrasound
Description: The presence of umbilical hernia in patients with cholelithiasis is detected by ultrasound of the superficial tissue of the umbilical region.
Study: NCT05669755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Participants will receive 2.4 mg cagrilintide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive 2.4 mg semaglutide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously.
Study: NCT06553768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maralixibat
Description: Maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), the study drug (maralixibat) will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of maralixibat. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (at least 16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), study drug will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of study drug. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.
Study: NCT04864392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNA043 Dosing Regimen A
Description: Injection to the knee

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNA043 Dosing Regimen B
Description: Injection to the knee

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNA043 Dosing Regimen C
Description: Injection to the knee

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNA043 Dosing Regimen D
Description: Injection to the knee

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection to the knee
Study: NCT05580562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dordaviprone (ONC201)
Description: Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dordaviprone (ONC201) + Placebo
Description: Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) or matching placebo on dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo (same number of capsules as the ONC201 dose) on dosing days
Study: NCT05440929

Intervention type: BEHAVIORAL
Intervention: Clinician Qualitative Interview
Description: Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications \& Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
Study: NCT04961528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 500 MG
Description: Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 500 mg x 3/day (= 500 mg / 8 hours) Treatments duration: 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 1 mg x 3/day (= 1 mg / 8 hours) Treatments duration: 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 5ml x 3/day (= 5 ml / 8 hours) Treatments duration: 3 days.
Study: NCT06637527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OK-101 0.05%
Description: 0.05% Ophthalmic Solution
Study: NCT05643599

Intervention type: DIETARY_SUPPLEMENT
Intervention: Mad Honey
Description: mad honey (80 mg/kg); (n:6)

Intervention type: DIETARY_SUPPLEMENT
Intervention: Normal Honey
Description: normal honey (80 mg/kg),(n:6)

Intervention type: DIETARY_SUPPLEMENT
Intervention: Control
Description: Control
Study: NCT06637527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OK-101 0.1%
Description: 0.1% Ophthalmic Solution
Study: NCT04883775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-2163
Description: MVT-2163 is administered intravenously as a PET imaging agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: MVT-5873 will be administered intravenously over at least 60 minutes.
Study: NCT06407973

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OMNI Surgical System
Description: The OMNI Surgical System is 510(k) cleared and indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost plus adjunctive glaucoma medication
Description: * Latanoprost ophthalmic solution (0.005%) is a topical prostaglandin F2 analog used in the treatment of Glaucoma.~* Adjunctive topical glaucoma medication(s) as selected by the Investigator
Study: NCT06506903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Avalus Ultra
Description: Surgical aortic valve replacement with the Medtronic Avalus Ultra bioprosthesis for management of aortic stenosis and regurgitation.
Study: NCT05976347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 MG
Description: Fluoxetine 20 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 MG
Description: Duloxetine 30 mg once daily
Study: NCT06637527

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04750226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: Solution for continuous subcutaneous infusion (CSCI).
Study: NCT05976347

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Referral to behavioral health and resources for addressing depressive symptoms
Study: NCT05826600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMX-0407
Description: Dose escalation, Dose expansion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMX-0407
Description: Dose escalation, Dose expansion
Study: NCT05950243

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire survey for data collection
Study: NCT05557123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEDI-app
Description: MEDI-app based feedback algorithm. The app based feedback algorithm will check and remind the patients of taking medication.
Study: NCT06108544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: Specified drug on specified days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified drug on specified days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast
Description: Specified drug on specified days.
Study: NCT04475393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carmat Total Artificial Heart
Description: Heart Replacement Therapy
Study: NCT05501054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciforadenant
Description: Given by PO
Study: NCT05456295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Custom Dynamic Orthosis (CDO)
Description: The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg below the knee. The design of the proximal cuff will differ between CUFF-A, CUFF-B, CUFF-C, CUFF-D.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Custom Dynamic Orthosis (CDO)
Description: The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg below the knee. The design of the proximal cuff will differ between CUFF-A, CUFF-B, CUFF-C, CUFF-D.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Custom Dynamic Orthosis (CDO)
Description: The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg below the knee. The design of the proximal cuff will differ between CUFF-A, CUFF-B, CUFF-C, CUFF-D.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Custom Dynamic Orthosis (CDO)
Description: The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg below the knee. The design of the proximal cuff will differ between CUFF-A, CUFF-B, CUFF-C, CUFF-D.
Study: NCT06223516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) ABBV-383
Description: SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) ABBV-383
Description: SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) ABBV-383
Description: SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ABBV-383
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ABBV-383
Description: IV Infusion
Study: NCT06465069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4052031
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4052031
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4052031
Description: Intravenous
Study: NCT04573023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-141
Description: IV infusion, 2.0 mg/kg/week

Intervention type: DRUG
Group type: OTHER
Intervention: Idursulfase
Description: IV infusion

Intervention type: DRUG
Group type: OTHER
Intervention: JR-141 or Idursulfase
Description: The subjects who have achieved the pre-specified criteria\* are able to change the drug.~\*If a subject in Idursulfase group shows decline in their neurocognitive outcome, idursulfase can be switched to JR-141.~If a subject in JR-141 group shows decline in their peripheral outcome, JR-141 will be switched to idursulfase.
Study: NCT06555016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reactive balance training
Description: Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reactive balance training
Description: Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.
Study: NCT05200611

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal Immunochemical Test
Description: Participants with positive fecal immunochemical test results were further examined by colonoscopy.
Study: NCT05103670

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA
Description: 32 patients will undergo a Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA at the inclusion and 3 months later.
Study: NCT04952402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Study-provided Moderna mRNA-1273 COVID-19 vaccine
Description: Participants received a two-dose series (100 µg (0.5 mL) was administered intramuscularly (IM) at Day 0 and Day 28).
Study: NCT06555016

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Walking
Description: Overground walking.
Study: NCT05949684

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Specified dose on specified days
Study: NCT06239532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC+TAE
Description: Procedure: HAIC+TAE After successful percutaneous hepatic artery cannulation for continuous pumping of drugs. Oxaliplatin(85 mg/m2); Raltitrexed (3 mg/m2) ，continuous infusion for 3 hours. HAIC was performed at an interval of at least 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Drug: Tislelizumab(200 mg) will be administered by IV infusion every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Drug: Surufatinib was taken orally after meals, once a day, with 3-5 capsules (50mg/capsule) each time.
Study: NCT06019663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Artificial Intelligence intervention for Self-Harm prevention Application (AISHA) is a mobile intervention based on Y-CMAP
Description: YCMAP is a Youth culturally adapted manual assisted psychological intervention based on CBT principles. The therapy focuses on current problems that contributed to the self-harm episode. Therapists and adolescent clients choose from a list of techniques those which are most relevant to the client's problems. Therapy is therefore adapted to fit with the client's problems and primarily utilises problem solving, CBT, and dialectical therapy strategies to bring about change.
Study: NCT04651439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Injection of ZARZIO 30 MU/0,5mL and/or ZARZIO 48 MU/0,5mL, over a period of 5 consecutive days (1 injection per day during 30 minutes - - day 1 : set up standard treatment). The filgrastim solution will be diluted in 20 mL of 5% Glucose. The dose of ZARZIO administrated depends of the patient's weight :~* 20 to \< 30kg = 0,3 mL of ZARZIO 48 MU/0,5mL (subcutaneous route)~* 30 to \< 60kg = 0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 60 to \< 90kg = 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* 90 to \< 120kg = 2x0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 120 to 150kg = 0,5 mL of ZARZIO 30 MU/0,5mL + 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* \> 150kg = 2x0,5 mL of ZARZIO 48 MU/0,5mL (by IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of 20 mL of Glucose 5% solution over a period of 5 consecutive days (1 injection per day during 30 minutes - day 1 : set up standard treatment). The dose given is equivalent to that used for filgrastim :~* 20 to \< 30kg = placebo not available because the injection must be done subcutaneously so the blind cannot be respected.~* 30 to \< 60kg = 20mL of Glucose 5% solution (by IV)~* 60 to \< 90kg = 20mL of Glucose 5% solution (by IV)~* 90 to \< 120kg = 20mL of Glucose 5% solution (by IV)~* 120 to 150kg = 20mL of Glucose 5% solution (by IV)~* \> 150kg = 20mL of Glucose 5% solution (by IV)
Study: NCT06358664

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy
Description: Standard pars plana vitrectomy will be performed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy
Description: Standard pars plana vitrectomy will be performed
Study: NCT05949684

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Specified dose on specified days